Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.5%

Neg 0% Neu 87.5% Pos 0%

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.

Comments

No comments yet. Be the first!